Dr Reddy S Lab
- All
- News
- Videos
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Labs Sheds 11% After Profit Falls 1.5% To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Shilpa Medicare Rallies 26% In Two Days On Tie Up To Make Sputnik Vaccine
Shilpa Medicare rallied for second straight session on Tuesday after it tied up with Dr Reddy's Labs to make Sputnik V Vaccine.
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Sensex Tumbles Over 400 Points, Nifty Settles Below 14,500
Tata Consumer Products dived nearly 5 per cent to top the loser's list on the BSE, while pharma stocks such as Cipla, Dr Reddy's and Divi's Lab lost 1-3 per cent each
-
Sputnik V Vaccine's India Maker Clarifies Day After Announcing Price
A day after announcing that Russia's Sputnik V vaccine could be sold at $10 (around Rs 750) a dose in India, its manufacturer Dr Reddy's Labs clarified that discussions on the price are still on and there is no final decision yet.
-
Sputnik V Shot To Cost Rs 750, To Arrive By May-June: Dr Reddy's To NDTV
Russia's Sputnik V Covid vaccine will be sold at $10 (around Rs 750) a dose in India, its manufacturer Dr Reddy's Labs has told NDTV.
-
Dr Reddy's Labs Slides Despite Government Go-Ahead For Sputnik Vaccine
The company's shares had opened at a high of Rs 5,200 per share. They had closed at Rs 4,989 on Monday.
-
Stocks To Watch In Trade: HDFC Bank, Dr Reddy's Lab, Wipro
HDFC Bank, on Saturday, reported a 18.1 rise in net profit to Rs 8,758.3 crore in the October-December quarter; total income increased to Rs 37,522 crore compared to Rs 36,039 crore in the year-ago period
-
Dr Reddy's Labs Commences Clinical Trials Of Sputnik V Vaccine; Stock Gains 1%
In September 2020, Dr. Reddy's and RDIF had entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.
-
Stocks To Watch: Coal India, Dr Reddy's Labs, Auto Shares In Focus Today
List of Stocks in Focus Today: Auto companies, including Tata Motors, Hero MotoCorp and Eicher Motors, are set to hog the limelight on the bourses after reporting stellar sales performance for the month of November
-
Dr. Reddy's And RDIF Commence Clinical Trials For Sputnik V Vaccine In India
The clinical trials are being conducted by JSS Medical Research as the clinical research partner
-
Dr Reddy's Isolates Data Centre Services After Cyberattack, Shares Fall 4%
Cyber-Attack: Dr Reddy's Labs said on Thursday it had isolated all its data center services as a preventive measure following a cyber-attack.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Dr Reddy's Labs Gains On Launching Eye Allergy Drop In US Market
Olopatadine Hydrochloride Ophthalmic Solution USP is equivalent of Novartis's Pataday and is indicated for the temporary relief of itchy eyes .
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Labs Sheds 11% After Profit Falls 1.5% To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Shilpa Medicare Rallies 26% In Two Days On Tie Up To Make Sputnik Vaccine
Shilpa Medicare rallied for second straight session on Tuesday after it tied up with Dr Reddy's Labs to make Sputnik V Vaccine.
-
Dr Reddy's Lab Net Profit Declines 28% To Rs 553.5 Crore In March Quarter
Dr Reddy's Lab Q4 FY21 Results: Dr Reddy's Laboratories announced its January-March quarter results, reporting a 27.5 per cent decline in net profit year-on-year at Rs 553.5 crore.
-
Sensex Tumbles Over 400 Points, Nifty Settles Below 14,500
Tata Consumer Products dived nearly 5 per cent to top the loser's list on the BSE, while pharma stocks such as Cipla, Dr Reddy's and Divi's Lab lost 1-3 per cent each
-
Sputnik V Vaccine's India Maker Clarifies Day After Announcing Price
A day after announcing that Russia's Sputnik V vaccine could be sold at $10 (around Rs 750) a dose in India, its manufacturer Dr Reddy's Labs clarified that discussions on the price are still on and there is no final decision yet.
-
Sputnik V Shot To Cost Rs 750, To Arrive By May-June: Dr Reddy's To NDTV
Russia's Sputnik V Covid vaccine will be sold at $10 (around Rs 750) a dose in India, its manufacturer Dr Reddy's Labs has told NDTV.
-
Dr Reddy's Labs Slides Despite Government Go-Ahead For Sputnik Vaccine
The company's shares had opened at a high of Rs 5,200 per share. They had closed at Rs 4,989 on Monday.
-
Stocks To Watch In Trade: HDFC Bank, Dr Reddy's Lab, Wipro
HDFC Bank, on Saturday, reported a 18.1 rise in net profit to Rs 8,758.3 crore in the October-December quarter; total income increased to Rs 37,522 crore compared to Rs 36,039 crore in the year-ago period
-
Dr Reddy's Labs Commences Clinical Trials Of Sputnik V Vaccine; Stock Gains 1%
In September 2020, Dr. Reddy's and RDIF had entered into a partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses in India.
-
Stocks To Watch: Coal India, Dr Reddy's Labs, Auto Shares In Focus Today
List of Stocks in Focus Today: Auto companies, including Tata Motors, Hero MotoCorp and Eicher Motors, are set to hog the limelight on the bourses after reporting stellar sales performance for the month of November
-
Dr. Reddy's And RDIF Commence Clinical Trials For Sputnik V Vaccine In India
The clinical trials are being conducted by JSS Medical Research as the clinical research partner
-
Dr Reddy's Isolates Data Centre Services After Cyberattack, Shares Fall 4%
Cyber-Attack: Dr Reddy's Labs said on Thursday it had isolated all its data center services as a preventive measure following a cyber-attack.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Dr Reddy's Labs Gains On Launching Eye Allergy Drop In US Market
Olopatadine Hydrochloride Ophthalmic Solution USP is equivalent of Novartis's Pataday and is indicated for the temporary relief of itchy eyes .
